Robot-assisted radical prostatectomy (RARP) is widely used because of the many advantages of a robotic approach. The da Vinci Si robot is one of the most commonly used surgical robot systems, but it may be associated with higher costs owing to the use of consumable surgical supplies. Our aim was to conduct a preliminary investigation of the capability of the MP1000 system for RARP.
In this prospective, multicentre, single-blinded study, we randomly assigned 42 patients scheduled to undergo RARP between April and September 2021 to a da Vinci Si group (control) or an MP1000 group (intervention). Patients underwent RARP performed using the assigned robotic system and were followed up at 3-mo intervals. The primary outcome was the rate of conversion to open/laparoscopic surgery. Secondary outcomes were installation and operation times, intraoperative blood loss, postoperative surgical margin status, hospital stay, incontinence, complications, safety indicators, and surgeon ergonomics.
All procedures were successfully completed without conversion to open/laparascopic surgery or major complications. Secondary outcomes, including oncological and ergonomic indicators, did not differ significantly between the groups over the study period. One patient in the control group experienced dysuria (Clavien-Dindo grade 3). No patients had incontinence at 3 mo. A limitation of the study is the small sample size.
RARP with the MP1000 system is feasible, safe, and effective in the management of localised prostate cancer.
We assessed the effectiveness and safety of the new MP1000 robot system for robot-assisted removal of the prostate in comparison to the da Vinci Si robot. We found no difference in effectiveness or safety among 42 patients with prostate cancer who were assigned randomly to one of the two systems. We conclude that the MP1000 is a suitable robot for this surgery.
European urology open science. 2024 Apr 25*** epublish ***
Shaoxi Niu, Liyan Ao, Yu Gao, Fangjian Zhou, Wang He, Jin Tao, Shengjie Guo, Baojun Wang, Xing Ai, Hongzhao Li, Xin Ma, Xuepei Zhang, Jian Huang, Xu Zhang
Department of Urology, Third Medical Centre, Chinese PLA General Hospital, Beijing 100039, China., Department of Urology, Sun Yat-sen University Cancer Centre, Guangzhou, China., Department of Urology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China., Department of Urology, First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.